Pegylated liposomal doxorubicin in ovarian cancer

International Journal of Nanomedicine

Volumn 1, Issue 3, 2006, Pages 229-239

  Green, Andrew E ^a   Rose, Peter G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Ovarian cancer; Pegylated lipopsomal doxorubicin

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; DRUG CARRIER; LIPOSOME; MACROGOL DERIVATIVE;

CHEMISTRY; FEMALE; HUMAN; METHODOLOGY; NANOMEDICINE; OVARY TUMOR; REVIEW;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; LIPOSOMES; NANOMEDICINE; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 34548804371     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. American Cancer Society. 2006. Who gets ovarian cancer? [online]. Accessed 3 March 2006. URL: http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_women_get_ovarian_cancer_33.asp?sitearea=.
2. Androulakis N, Kouroussis C, Mavroudis D, et al. 2002. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours. Eur J Cancer, 38:1992-7.
3. Arcuri C, Sorio R, Tognon G, et al. 2006. A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma. Tumori, 90:556-61.
4. Campos SM, Penson RT, Mays AR, et al. 2001. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol, 81:206-12.
5. Campos SM, Matulonis UA, Penson RT, et al. 2003. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol, 90:610-18.
6. Cattel L, Ceruti M, Dosio F. 2003. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori, 89:237-49.
7. Cesano A, Lane SR, Poulin R, Ross G, Fields SZ. 1999. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol, 15:1233-8.
8. Chou HH, Wang KL, Chen CA, et al. 2005. Pegylated liposomal doxorubicin (Lipo-Dox(R)) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol (epub ahead of print).
9. Copeland LJ, Bookman M, Trimble E. 2003. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol, 90:S1-7.
10. D'Agostino G, Ferrandina G, Ludovisi M, et al. 2003. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer, 89:1180-4.
11. Drake RD, Lin WM, King M, et al. 2004. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol, 94:320-4.
12. Fracasso PM, Blum KA, Ma MK, et al. 2005. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer, 93:46-53.
13. Fracasso PM, Blum KA, Tan BR, et al. 2002. Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies. Cancer, 95:2223-9.
14. Fracasso PM, Rodriguez LC, Herzog TJ, et al. 2003. Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. Cancer, 98:610-7.
15. Ferrandina G, Paris I, Ludovisi M, et al. 2005. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol, 98:267-73.
16. Ferrero JM, Wever B, Lepille D, et al. 2004. Carboplatin (PA) and pegylated liposomal doxorubicin (CA:PACA regimen) in patients with advanced ovarian cancer in late relapse (>6 months) (AOCLR): results of a GINECO phast II trial. Proc Am Soc Clin Oncol, 23:454s.
17. Garcia AA, Roman L, Muderspach L, et al. 2005. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. Cancer Invest, 23:665-70.
18. Gibbs DD, Pyle L, Allen M, et al. 2002. A phase I dose-finding study of a combination of Pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br J Cancer, 86:1379-84.
19. Goncalves A, Braud AC, Viret F, et al. 2003. Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors. Anticancer Res, 23:3543-8.
20. Gordon AN, Fleagle JT, Guthrie D, et al 2001. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol, 19:3312-22.
21. Gordon AN, Granai CO, Rose PG, et al. 2000. Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol, 18:3093-100.
22. Gordon AN, Tonda M, Sun S, et al. 2004. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol, 95:1-8.
23. Gronlund B, Hogdall C, Christensen IJ, et al. 2004. Is stabilization of disease a useful indicator of survival in second-line treatment of ovarian carcinoma pre-treated with paclitaxel-Platinum? Gynecol Oncol, 94:409-15.
24. Jain RK. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307:58-62.
25. Katsaros D, Oletti MV, Rigault de la Longrais IA, et al. 2005. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. Ann Oncol, 16:300-6.
26. Kim RJ, Peterson G, Kulp B, Zanotti KM,et al. 2005 Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol, 97:374-8.
27. Lorusso D, Naldini A, Testa A, et al. 2004. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? Oncology, 67:243-9.
28. Lyass O, Hubert A, Gabizon AA. 2001. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res, 7:3040-6.
29. Markman M, Kennedy A, Webster K, et al. 2000. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol, 78:369-72.
30. Mirchandani D, Hochster H, Hamilton A, et al. 2005. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res, 11:5912-9.
31. Muggia FM, Hainsworth JD, Jeffers S, et al. 1997. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol, 15:987-93
32. Nagore E, Insa A, Sanmartin O. 2000. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol, 1:225-34.
33. Nicoletto MO, Falci C, Pianalto D, et al. 2006. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol, 100:318-23.
34. O'Brien ME, Wigler N, Inbar M, et al. 2004. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol, 15:440-9.
35. O'Byrne KJ, Bliss P, Graham JD, et al. 2002. A Phase III study of Doxil/Caylex versus paclitaxel in platinum treated taxane naive relapsed ovarian cancer. Proc Am Soc Clin Oncol, 21:203a nr 808.
36. Petru E, Angleitner-Boubenizek L, Reinthaller A, et al. 2006. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and-resistant ovarian cancer after previous platinum-taxane therapy: A phase II Austrian AGO study. Gynecol Oncol (epub ahead of print).
37. Potamianou A, Androulakis N, Papakotoulas P, et al. 2005. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. Oncology, 69:348-53.
38. Recchia F, De Filippis S, Saggio G, et al. 2003. Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer. Anticancer Drugs, 14:633-8.
39. Rose PG. 2004. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarain cancer. The Oncologist, 10:205-14.
40. Rose PG, Greer BE, Markman M, et al. 2000. A phase I study of paclitaxel, carboplatin, and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol, 19:387a.
41. Rose PG, Maxson JH, Fusco N, et al. 2001. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol, 82:323-8.
42. Rose PG, Rodriguez M, Walker J, et al. 2002. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study. Gynecol Oncol, 85:136-9.
43. Ryan CW, Fleming GF, Janisch L, et al. 2000. A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol, 23:297-300.
44. Skarlos DV, Kalofonos HP, Fountzilas G, et al. 2005. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Res, 25:3103-8.
45. Tambaro R, Greggi S, Iaffaioli RV, et al. 2003. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. Ann Oncol, 14:1406-11.
46. Uziely B, Jeffers S, Isacson R, et al. 1995. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol, 13:1777-85.
47. Valerio MR, Tagliaferri P, Raspagliesi F, et al. 2006. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer, 16(Suppl 1):79-85.
48. Verhaar-Langereis M, Karakus A, van Eijkeren M, et al. 2006. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int J Gynecol Cancer, 16:65-70.
49. Vorobiof DA, Rapoport BL, Slabber CF, et al. 2004. Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer. Proc Am Soc Clin Oncol, 23:471s.
50. Waterhouse DN, Tardi PG, Mayer LD, et al. 2001. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf, 24:903-20.
51. Wilailak S, Linasmita V. 2004. A study of pegylated liposomal Doxorubicin in platinum-refractory epithelial ovarian cancer. Oncology, 67:183-6.